IL5 and hypereosinophilic syndrome: Therapies include corticosteroids, immunosuppressants and Mepolizumab (3, 4), an anti-IL-5 drug directed against type 2 (T2)-eosinophilic inflammation previously approved for the treatment of severe eosinophilic asthma and recently approved also for severe CRSwNP, hypereosinophilic syndrome (HES) and EGPA.